Prediction of neutropenia-related effects of a new combination therapy with the anticancer drugs BI 2536 (a Plk1 inhibitor) and pemetrexed.
Soto
E
E
Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, Spain. elena.soto@pfizer.com
Staab
A
A
Freiwald
M
M
Munzert
G
G
Fritsch
H
H
Döge
C
C
Trocóniz
I F
IF